Kepler Capital Markets reissued their reduce rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report report published on Thursday morning. Kepler Capital Markets currently has a GBX 1,520 ($19.80) target price on the stock.

A number of other equities analysts also recently commented on GSK. UBS AG set a GBX 1,600 ($20.84) target price on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, April 27th. J P Morgan Chase & Co restated a neutral rating on shares of GlaxoSmithKline plc in a research note on Monday, July 24th. Investec restated a buy rating and issued a GBX 1,800 ($23.45) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th. S&P Global set a GBX 1,500 ($19.54) target price on shares of GlaxoSmithKline plc and gave the stock a sell rating in a research note on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research note on Wednesday, July 26th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of GBX 1,734.73 ($22.60).

GlaxoSmithKline plc (GSK) opened at 1526.00 on Thursday. The stock’s 50 day moving average is GBX 1,638.77 and its 200 day moving average is GBX 1,627.17. The stock’s market capitalization is GBX 74.59 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/glaxosmithkline-plc-longsk-rating-reiterated-by-kepler-capital-markets/1463348.html.

The business also recently declared a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.23%.

In related news, insider Victoria Whyte sold 4,820 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($22.06), for a total transaction of £81,602.60 ($106,308.75). Also, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, July 26th. The shares were acquired at an average cost of GBX 1,599 ($20.83) per share, with a total value of £36,249.33 ($47,224.24). In the last ninety days, insiders acquired 3,150 shares of company stock valued at $5,054,075.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.